BR112018069591A2 - gel viscoelástico e método para o controle de níveis de glicose no sangue - Google Patents
gel viscoelástico e método para o controle de níveis de glicose no sangueInfo
- Publication number
- BR112018069591A2 BR112018069591A2 BR112018069591-2A BR112018069591A BR112018069591A2 BR 112018069591 A2 BR112018069591 A2 BR 112018069591A2 BR 112018069591 A BR112018069591 A BR 112018069591A BR 112018069591 A2 BR112018069591 A2 BR 112018069591A2
- Authority
- BR
- Brazil
- Prior art keywords
- gel
- controlling blood
- blood glucose
- glucose levels
- viscoelastic gel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a um gel viscoelástico compreendendo uma quantidade terapeuticamente efetiva de liraglutida, cujo gel não contem copolímeros de bloco ou de enxerto, e cujo gel é caracterizado por um valor de rendimento a partir de 200 pa a 3000 pa e um ponto de fluxo a partir de 300 pa a 3500 pa. a invenção também proporciona um método para o controle de níveis de açúcar no sangue por intermédio da administração subcutânea de referido gel uma vez por semana ou uma vez a cada duas semanas semana a um indivíduo necessitado de tal tratamento. o método de preparação de referido gel também é proporcionado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621011454 | 2016-03-31 | ||
| IN201621011454 | 2016-03-31 | ||
| PCT/IN2016/050447 WO2017168435A1 (en) | 2016-03-31 | 2016-12-16 | Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018069591A2 true BR112018069591A2 (pt) | 2019-04-16 |
Family
ID=59963648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018069591-2A BR112018069591A2 (pt) | 2016-03-31 | 2016-12-16 | gel viscoelástico e método para o controle de níveis de glicose no sangue |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190105268A1 (pt) |
| EP (1) | EP3436050A4 (pt) |
| JP (1) | JP2019510048A (pt) |
| CN (1) | CN108883157A (pt) |
| AU (1) | AU2016400406A1 (pt) |
| BR (1) | BR112018069591A2 (pt) |
| CA (1) | CA3018670A1 (pt) |
| MX (1) | MX2018011893A (pt) |
| RU (1) | RU2018134132A (pt) |
| WO (1) | WO2017168435A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019229719A1 (en) | 2018-06-01 | 2019-12-05 | Sun Pharma Advanced Research Company Limited | An injection device |
| KR102583029B1 (ko) * | 2020-05-28 | 2023-09-26 | 주식회사 아울바이오 | 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법 |
| WO2023189273A1 (ja) * | 2022-03-28 | 2023-10-05 | 富士フイルム株式会社 | 生体用組成物 |
| WO2023189270A1 (ja) * | 2022-03-28 | 2023-10-05 | 富士フイルム株式会社 | 生体用組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2594718C (en) * | 2005-01-14 | 2012-01-24 | Camurus Ab | Gnrh analogue formulations |
| US8546326B2 (en) * | 2005-06-06 | 2013-10-01 | Camurus Ab | Glp-1 analogue formulations |
| EP1891941A1 (en) * | 2006-08-11 | 2008-02-27 | OctoPlus Technologies B.V. | Aqueous gels comprising microspheres |
| US20140004198A1 (en) * | 2011-01-19 | 2014-01-02 | Novo Nordisk A/S | Glp-1 particles and compositions |
| BR112014013691A2 (pt) * | 2011-12-05 | 2017-06-13 | Camurus Ab | pré-formulação, métodos para distribuição de um agente ativo de peptídeo, para a preparação de uma composição cristalina líquida, de tratamento ou profilaxia de um sujeito, processo para a formação de uma pré-formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração de pré-preenchido, e, kit |
| US9314422B2 (en) * | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| CN104069485A (zh) * | 2013-03-27 | 2014-10-01 | 深圳翰宇药业股份有限公司 | 一种利拉鲁肽原位凝胶制剂及其制备方法 |
| CN104840415B (zh) * | 2014-02-19 | 2019-03-15 | 香港浸会大学 | 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法 |
-
2016
- 2016-12-16 RU RU2018134132A patent/RU2018134132A/ru not_active Application Discontinuation
- 2016-12-16 CA CA3018670A patent/CA3018670A1/en not_active Abandoned
- 2016-12-16 MX MX2018011893A patent/MX2018011893A/es unknown
- 2016-12-16 BR BR112018069591-2A patent/BR112018069591A2/pt not_active Application Discontinuation
- 2016-12-16 AU AU2016400406A patent/AU2016400406A1/en not_active Abandoned
- 2016-12-16 EP EP16896678.6A patent/EP3436050A4/en not_active Withdrawn
- 2016-12-16 US US16/089,776 patent/US20190105268A1/en not_active Abandoned
- 2016-12-16 JP JP2018550832A patent/JP2019510048A/ja active Pending
- 2016-12-16 CN CN201680084225.7A patent/CN108883157A/zh active Pending
- 2016-12-16 WO PCT/IN2016/050447 patent/WO2017168435A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP3436050A4 (en) | 2020-01-15 |
| WO2017168435A1 (en) | 2017-10-05 |
| CA3018670A1 (en) | 2017-10-05 |
| RU2018134132A (ru) | 2020-04-30 |
| US20190105268A1 (en) | 2019-04-11 |
| EP3436050A1 (en) | 2019-02-06 |
| AU2016400406A1 (en) | 2018-10-04 |
| MX2018011893A (es) | 2019-01-10 |
| JP2019510048A (ja) | 2019-04-11 |
| CN108883157A (zh) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018069591A2 (pt) | gel viscoelástico e método para o controle de níveis de glicose no sangue | |
| MX2022005291A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| EA201790405A1 (ru) | Композиции и способы лечения метаболических расстройств | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
| GEP20217249B (en) | Stable liquid pharmaceutical preparation | |
| MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
| WO2017053732A3 (en) | Composition and method for treating complement-mediated disease | |
| WO2017041001A3 (en) | Insulin immunoglobulin fusion proteins | |
| EA201792530A1 (ru) | Пероральная композиция целекоксиба для лечения боли | |
| EP4137147A3 (en) | Uses of abaloparatide in reducing fracture risk | |
| WO2018226992A8 (en) | Tau aggregation inhibitors | |
| BR112017026853A2 (pt) | composição de ação prolongada | |
| JOP20210201A1 (ar) | مركب لخفض جلوكوز الدم | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| MD4710C1 (ro) | Tratamente terapeutice pe bază de anamorelin | |
| BR112018017247A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença? | |
| BR112018017240A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante? | |
| IL257813A (en) | Combined compositions for controlling blood sugar levels, hepatoprotection, and for prevention and treatment of related medical conditions | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| WO2018136779A3 (en) | OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS | |
| MX2020001256A (es) | Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos. | |
| MX2019014771A (es) | Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |